

Biophytis shares and BSA trading is suspended pending a new press release

Paris (France), Cambridge (Massachusetts, USA), September 30, 2020, 8.00 a.m. CEST – BIOPHYTIS (Euronext Growth Paris) asked Euronext Paris to suspend the trading of its shares (ISIN code : FR0012816825-ALBPS) and BSA (ISIN code : FR0013507290-BPSBS) as from today 30th September 2020, pending the publication of a new press release.

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company specialized in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, including neuromuscular diseases.

Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in the United States and Europe. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company plans to start the clinical development (MYODA) in H2 2020.

Sarconeos (BIO101) is also being developed as a treatment for patients with COVID-19 related respiratory failure in a Phase 2/3 clinical study (COVA) in the United States, Europe and Latin America.

The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825). For more information visit www.biophytis.com

Biophytis Contact for Investor Relations

Evelyne Nguyen, CFO

evelyne.nguyen@biophytis.com

Media contact

Citigate Dewe Rogerson

Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussart

biophytis@citigatedewerogerson.com

Tel: +44 (0) 20 7638 9571 / +33 (0)6 59 42 29 35